FWBI

First Wave BioPharma, Inc. [FWBI] Stock Forecast

Q: What is First Wave BioPharma, Inc. stock symbol ?

First Wave BioPharma, Inc. is a US stock, located in Boca raton of Fl and trading under the symbol FWBI

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

FWBI Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

EPS has been increasing for the past 3 quarters (Quarter statements)

Does not have any significance market cap ($6.72M)

FWBI has less than 1 year of cash runway

Top 10 Correlated ETFs

FWBI

Top 10 Correlated Stocks

FWBI

In the News

FWBI Financial details

Company Rating

Neutral

Market Cap

6.72M

Income

-15.81M

Revenue

Book val./share

2.31

Cash/share

2.38

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

12 May 2024

P/E

-2.13

Forward P/E

PEG

0.26

P/S

P/B

11.28

P/C

1.16

P/FCF

-0.23

Quick Ratio

1.33

Current Ratio

1.6

Debt / Equity

0.23

LT Debt / Equity

0.04

EPS (TTM)

-84.45

EPS next Y

EPS next Q

EPS this Y

-89.83%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

-71.04%

SMA20

-40%

SMA50

-40%

SMA100

-40%

Inst Own

0.15%

Inst Trans

ROA

-294%

ROE

-724%

ROC

-4.05%

Gross Margin

Oper. Margin

Profit Margin

Payout

-1%

Shs Outstand

Shs Float

Target Price

52W Range

2.75-73.0

52W High

-96.23%

52W Low

+37.5%

RSI

Rel Volume

0.22

Avg Volume

122.57K

Volume

26.89K

Perf Week

-19.59%

Perf Month

-61.59%

Perf Quarter

-52.42%

Perf Half Y

-60.49%

Beta

1.214

Volatility

0.25%, 1.01%

Prev Close

-5.17%

Price

2.75

Change

-6.14%

FWBI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-29.24K	-57.19K	-27.8K	-461.72	-46.96
Operating cash flow per share	-26.28K	-16.57K	-15.19K	-622.19	-36.8
Free cash flow per share	-26.33K	-16.58K	-20.05K	-622.19	-38.29
Cash per share	329.24	8.95K	3.88K	37.95	11.04
Book value per share	8.65K	-3.9K	-3.68K	76.36	10.71
Tangible book value per share	-1.27K	-11.19K	-4.58K	29.46	5.7
Share holders equity per share	8.65K	-3.9K	-3.68K	76.36	10.71
Interest debt per share	3.82K	9.56K	490.12	25.05	2.39
Market cap	23.32M	27.58M	12.9M	4.4M	1.41M
Enterprise value	24.75M	22.15M	5.68M	3.93M	-1.47M
P/E ratio	-1.49	-0.71	-0.22	-0.27	-0.09
Price to sales ratio	0	0	0	0	0
POCF ratio	-1.66	-2.46	-0.4	-0.2	-0.11
PFCF ratio	-1.66	-2.46	-0.3	-0.2	-0.11
P/B Ratio	5.05	-10.45	-1.65	1.61	0.39
PTB ratio	5.05	-10.45	-1.65	1.61	0.39
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-1.8	-0.86	-0.1	-0.3	0.09
EV to operating cash flow	-1.76	-1.97	-0.18	-0.18	0.12
EV to free cash flow	-1.76	-1.97	-0.13	-0.18	0.11
Earnings yield	-0.67	-1.4	-4.58	-3.76	-11.18
Free cash flow yield	-0.6	-0.41	-3.3	-5.07	-9.12
Debt to equity	0.35	-0.24	-0.13	0.32	0.23
Debt to assets	0.18	0.05	0.09	0.16	0.12
Net debt to EBITDA	-0.1	0.21	0.13	0.04	0.18
Current ratio	0.8	0.51	0.77	1.37	1.58
Interest coverage	-33.98	-4.53	-5.26K	-798.42	702.08
Income quality	0.92	0.34	0.55	1.53	0.78
Dividend Yield	0.07	0.3	349.45K	0.01	0.22
Payout ratio	-0.11	-0.21	-76.29K	0	-0.02
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.59	0.38	0.16	0.31	0.24
Capex to operating cash flow	0	0	0.32	0	0.04
Capex to revenue	0	0	0	0	0
Capex to depreciation	-0.02	-0.01	-19.03	0	-17.08
Stock based compensation to revenue	0	0	0	0	0
Graham number	75.42K	70.85K	47.98K	890.65	106.39
ROIC	-2.41	16.19	9.31	-3.68	-3.45
Return on tangible assets	-4.33	-4.85	-5.98	-4.42	-3.04
Graham Net	-3.99K	-13.42K	-5.35K	-35.22	1.28
Working capital	-877.35K	-7.68M	-2.88M	929.27K	1.82M
Tangible asset value	-676.53K	-7.57M	-9.73M	1.06M	1.92M
Net current asset value	-877.35K	-7.69M	-10.19M	715.21K	1.68M
Invested capital	0.35	-0.24	-0.13	0.32	0.23
Average receivables	2.9M	1.59M	275.74K	46.51K	46.51K
Average payables	2.21M	1.89M	2.12M	1.7M	637.16K
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	828.25	996.04	1.82K	2.47K	6.91K
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0.44	0.37	0.2	0.15	0.05
Inventory turnover	0	0	0	0	0
ROE	-3.38	14.66	7.55	-6.05	-4.38
Capex per share	-45.13	-6.15	-4.86K	0	-1.49

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-114.42	-35.85	-36.89	-9.08	-2.63
Operating cash flow per share	-112.41	-24.95	-24.32	-8.81	-2.2
Free cash flow per share	-112.41	-24.95	-24.32	-8.81	-2.52
Cash per share	27.4	18.1	10.89	8.7	2.38
Book value per share	55.12	23.79	7.77	8.67	2.31
Tangible book value per share	21.27	9.02	-7.07	4.22	1.23
Share holders equity per share	55.12	23.79	7.77	8.67	2.31
Interest debt per share	17.89	5.73	3.58	0.61	0.53
Market cap	6.1M	6.11M	3.63M	2.19M	6.56M
Enterprise value	5.62M	4.69M	2.8M	-866.9K	3.67M
P/E ratio	-0.27	-0.37	-0.22	-0.16	-0.4
Price to sales ratio	0	0	0	0	0
POCF ratio	-1.09	-2.15	-1.32	-0.66	-1.91
PFCF ratio	-1.09	-2.15	-1.32	-0.66	-1.66
P/B Ratio	2.23	2.25	4.12	0.67	1.82
PTB ratio	2.23	2.25	4.12	0.67	1.82
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-1.42	-1.16	-0.67	0.25	-0.9
EV to operating cash flow	-1.01	-1.65	-1.01	0.26	-1.07
EV to free cash flow	-1.01	-1.65	-1.01	0.26	-0.93
Earnings yield	-0.93	-0.67	-1.15	-1.57	-0.63
Free cash flow yield	-0.92	-0.47	-0.76	-1.52	-0.6
Debt to equity	0.32	0.24	0.46	0.07	0.23
Debt to assets	0.16	0.12	0.09	0.04	0.12
Net debt to EBITDA	0.12	0.35	0.2	0.89	0.71
Current ratio	1.37	1.34	0.72	1.6	1.58
Interest coverage	-368.1	-452.03	-807.58	-2.75K	-580.82
Income quality	1.4	0.7	0.66	0.97	0.84
Dividend Yield	0.01	0.01	0	0	0
Payout ratio	-0.01	-0.02	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.31	0.3	0.39	0.28	0.24
Capex to operating cash flow	0	0	0	0	0.15
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	-68.32
Stock based compensation to revenue	0	0	0	0	0
Graham number	376.69	138.52	80.3	42.07	11.68
ROIC	-0.83	-1.13	-2.73	-0.92	-0.89
Return on tangible assets	-1.52	-1.06	-1.58	-0.81	-0.79
Graham Net	-25.42	-6.51	-19.46	1.7	0.28
Working capital	929.27K	905.02K	-907.46K	1.49M	1.82M
Tangible asset value	1.06M	1.03M	-802.22K	1.59M	1.92M
Net current asset value	715.21K	708.49K	-1.09M	1.33M	1.68M
Invested capital	0.32	0.24	0.46	0.07	0.23
Average receivables	142.5K	56.51K	10K	0	0
Average payables	2.15M	594.9K	1.03M	1.09M	566.78K
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	2.87K	1.85K	6.19K	2.23K	6.82K
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0.03	0.05	0.01	0.04	0.01
Inventory turnover	0	0	0	0	0
ROE	-2.08	-1.51	-4.75	-1.05	-1.14
Capex per share	0	0	0	0	-0.32

FWBI Frequently Asked Questions

What is First Wave BioPharma, Inc. stock symbol ?

First Wave BioPharma, Inc. is a US stock , located in Boca raton of Fl and trading under the symbol FWBI

What is First Wave BioPharma, Inc. stock quote today ?

First Wave BioPharma, Inc. stock price is $2.75 today.

Is First Wave BioPharma, Inc. stock public?

Yes, First Wave BioPharma, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 122.57K
Market Capitalization 6.72M
Employee 9
CEO Mr. James R. Sapirstein M.B.A., R.Ph.
Headquarters Boca Raton,FL,US
IPO Date 2016-10-11
Website https://www.firstwavebio.com

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.